|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 388.90 DKK | +6.49% |
|
+1.95% | +19.57% |
| 01-16 | Health Care Up as Wegovy Pill Buoys Novo Nordisk -- Health Care Roundup | DJ |
| 01-16 | Sector Update: Health Care Stocks Retreat Late Afternoon | MT |
Evolution of the Average Target: Novo Nordisk A/S
Evolution of the Target Price: Novo Nordisk A/S
Changes in Analyst Recommendations: Novo Nordisk A/S
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +3.11% | |||||
| +6.97% | |||||
| -3.05% | |||||
| +14.32% | |||||
| -1.9% | |||||
| +8.49% | |||||
| -3.37% | |||||
| +4.27% | |||||
| +0.36% | |||||
| +7.43% | |||||
| Average | +3.66% | |||||
| Weighted average by Cap. | +3.93% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| BARCLAYS | James Gordon |
| BERENBERG | |
| DEUTSCHE BANK RESEARCH | Emmanuel Papadakis |
| JPMORGAN | Richard Vosser |
| UBS | Matthew Weston |
| alphavalue | Abhishek Raval |
| GOLDMAN SACHS | James Quigley |
| JEFFERIES | |
| Svenska Handelsbanken | |
| HSBC | |
| DZ BANK | Elmar Kraus |
| BERNSTEIN RESEARCH | Florent Cespedes |
| SEB Bank | |
| Morgan Stanley | |
| Berenberg Bank | |
| Rothschild & Co Redburn | |
| Kepler Cheuvreux | |
| BNP Paribas | |
| BNP Paribas Exane | |
| Intron Health | |
| BMO Capital | |
| Stifel Nicolaus | |
| Jyske Bank | |
| ODDO BHF | |
| AlphaValue/Baader Europe | |
| Argus | |
| Cantor Fitzgerald | |
| TD Cowen | |
| CREDIT SUISSE | Lorenzo Biasio |
| JPMorgan Chase | |
| Guggenheim | |
| Bryan, Garnier & Co. | |
| Deutsche Bank Securities | |
| DEUTSCHE BANK | Emmanuel Papadakis |
| Liberum Capital | |
| INDEPENDENT RESEARCH | Tobias Gottschalt |
| BANK OF AMERICA (BOFA) | Sachin Jain |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NOVO B Stock
- Consensus Novo Nordisk A/S
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition